Shares of Ocular Therapeutix Inc. rallied more than 13% late Monday after the Bedford, Mass., pharmaceutical company said it has amended its new-drug application for its eye drug Dextenza to account for an equipment change. Ocular said it has requested the Food and Drug Administration to consider the submission “a major amendment” and to extend the target action date of July 19 by three months since the company has addressed some of the FDA’s ongoing concerns about the drug’s manufacturing process. The stock ended the regular session down 8.9%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News